Homozygous Familial Hypercholesterolemia (HoFH) Overview
Learn About Homozygous Familial Hypercholesterolemia (HoFH)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Frederick Raal practices in Johannesburg, South Africa. Mr. Raal is rated as an Elite expert by MediFind in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). His top areas of expertise are Homozygous Familial Hypercholesterolemia (HoFH), Heterozygous Familial Hypercholesterolemia (HeFH), Familial Hypercholesterolemia, and High Cholesterol.
Daniel Gaudet practices in Montreal, Canada. Mr. Gaudet is rated as an Elite expert by MediFind in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). His top areas of expertise are High Cholesterol, Familial Lipoprotein Lipase Deficiency, Apolipoprotein C2 Deficiency, and Familial Hypertriglyceridemia.
Dirk Blom practices in Cape Town, South Africa. Mr. Blom is rated as an Elite expert by MediFind in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). His top areas of expertise are Homozygous Familial Hypercholesterolemia (HoFH), Familial Hypercholesterolemia, High Cholesterol, Defective Apolipoprotein B-100, and Hormone Replacement Therapy (HRT).
Summary: This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to \<12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDLC).
Summary: This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE...